31st Dec 2009 10:45
Immediate Release |
31 December 2009 |
TR-1 NOTIFICATION OF MAJOR INTEREST IN SHARES |
|||||
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
Alliance Pharma plc |
||||
2 Reason for the notification (please tick the appropriate box or boxes): |
|||||
An acquisition or disposal of voting rights |
√ |
||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|||||
An event changing the breakdown of voting rights |
|||||
Other (please specify): |
|||||
3. Full name of person(s) subject to the notification obligation: iii |
Aviva plc & its subsidiaries |
||||
4. Full name of shareholder(s) (if different from 3.):iv |
Registered Holder: CUIM Nominee Limited 5,123,417*
*denotes direct interest BNP Paribas - London 3,300,771 Chase Nominees Limited 10,772,567 |
||||
5. Date of the transaction and date on which the threshold is crossed or reached: v |
29 December 2009 |
||||
6. Date on which issuer notified: |
30 December 2009 |
||||
7. Threshold(s) that is/are crossed or reached: vi, vii |
10% to <10% Change at Combined Interest Level |
8. Notified details: |
|||||||||||
A: Voting rights attached to shares viii, ix |
|||||||||||
Class/type of shares if possible using the ISIN CODE |
Situation previous to the triggering transaction |
Resulting situation after the triggering transaction |
|||||||||
Number of Shares |
Number of Voting Rights |
Number of shares |
Number of voting rights |
% of voting rights x |
|||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
|||||||
Ordinary SharesGB0031030819 |
20,746,755 |
20,746,755 |
19,196,755 |
5,123,417 |
14,073,338 |
2.65% |
7.28% |
||||
B: Qualifying Financial Instruments |
|||||||||||
Resulting situation after the triggering transaction |
|||||||||||
Type of financial instrument |
Expiration date xiii |
Exercise/ Conversion Period xiv |
Number of voting rights that may be acquired if the instrument is exercised/ converted. |
% of voting rights |
|||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
|||||||
Resulting situation after the triggering transaction |
|||||||
Type of financial instrument |
Exercise price |
Expiration date xvii |
Exercise/ Conversion period xviii |
Number of voting rights instrument refers to |
% of voting rights xix, xx |
||
Nominal |
Delta |
||||||
Total (A+B+C) |
|||||||
Number of voting rights |
Percentage of voting rights |
||||||
19,196,755 |
9.93% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi |
||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: Aviva plc (Parent Company) Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited) |
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See Section 4 |
|
11. Number of voting rights proxy holder will cease to hold: |
||
12. Date on which proxy holder will cease to hold voting rights: |
||
13. Additional information: |
Figures are based on the total number of voting rights of 193,319,398. |
|
14. Contact name: |
Neil Whittaker |
|
15. Contact telephone number: |
01603 684420 |
Related Shares:
Alliance PharmaAviva